FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Genetic Technologies Limited Granted Foundational Pharmacogenomic Patent ”
Genetic Technologies Limited (NASDAQ: GENE) surged over 14% in premarket trading after it was granted US Patent No. 11,031,098 – ‘Computer Systems and Methods for Genomic Analysis’.
The patent describes efficient methods for identifying variations that occur in the human genome and relating those variations to the genetic basis of disease and drug response.
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products.
For more information, please visit: Genetic Technologies Limited
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.
The post “The Buzz” Show: Genetic Technologies Limited (NASDAQ: GENE) Foundational Pharmacogenomic Patent first appeared on Financial Buzz .
For further details see:
“The Buzz” Show: Genetic Technologies Limited (NASDAQ: GENE) Foundational Pharmacogenomic Patent